Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer
NCT07249879Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC511B in small cell lung cancer (SCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicity Rate at 28 days, Adverse Events up to 15 years and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
GC511B
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07249879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249879.